arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Twist Bioscience Corp

TWST
$115.73 ▲ +4.79 (+4.32%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
36 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Twist Bioscience Corp faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.1B
Dividend Yield
Revenue Growth 19.3%
Op. Margin -41.4%
ROIC -10.1%
FCF / Share $-0.41
Trailing P/E
Price / Book 15.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$110.72M
↑ +19.3%
Net Income Profit after all expenses
$-44.02M
↓ -11.9%
Operating Margin Operating profit as % of sales
-41.4%
↓ -30.6% 7th
FCF / Share Free cash flow per share
$-0.41
↑ +27.6%
Long-Term Debt Long-term obligations
$625.00K
↓ -71.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
29
Cash Quality
64

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 36 quarters